Welcome!

News Feed Item

PDI Reports 2014 Second Quarter Financial Results

Management Will Host Conference Call Tomorrow August 14 at 8:30 am ET

PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the second quarter ended June 30, 2014. Summary financial and operational accomplishments include:

  • Revenue of $31.6 million for the second quarter of 2014
  • Adjusted EBITDA (a non-GAAP financial measure) of $(1.5) million for the second quarter of 2014
  • On August 13, 2014, PDI acquired Asuragen, Inc.'s miRInform Thyroid and miRInform Pancreas cancer test assets
  • Subsequent to the second quarter, Heiner Dreismann, Ph.D., a highly experienced molecular diagnostics executive and former President and CEO of Roche Molecular Systems, joined PDI's board of directors
PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise.

 

 

Condensed Summary Statements of Continuing Operations (Unaudited)

($'s in thousands, expect per share data)










2nd Quarter Ended


Six Months Ended




June 30,*


June 30,*




2014


2013


2014


2013











Revenue, net


$           31.6


$           37.2


$           64.4


$           80.2











Gross profit


4.8


6.8


9.9


15.3











Operating expenses:









   Compensation expense

3.9


4.9


7.4


9.1

   Other SG&A


3.5


2.8


6.5


4.8

         Total operating expenses

7.3


7.7


13.9


13.9











Operating (loss) income 

$           (2.5)


$            (0.8)


$           (4.0)


$             1.4











Provision for income tax

0.1


0.1


0.1


0.1

(Loss) income from continuing operations

$           (2.6)


$            (0.9)


$           (4.2)


$             1.2











Diluted (loss) income per share from continuing operations

$         (0.17)


$          (0.06)


$         (0.28)


$           0.08

  *Unaudited









 

CEO Comments

"We are extremely excited to announce the agreement to acquire specific diagnostic assets from Asuragen, Inc. The transaction is the first step for our Interpace Diagnostic subsidiary in expanding into higher growth, higher margin markets and starts to establish Interpace as a commercially focused molecular diagnostic subsidiary," said Nancy Lurker, CEO.

"The transaction includes two oncology assays, miRInform Thyroid and miRInform Pancreas, associated intellectual property, a large biobank with over 5,000 patient tissue samples, as well as, additional thyroid tests in development."

"In addition, Heiner Dreismann, Ph.D., has joined our board of directors and brings with him nearly 30 years of experience in the diagnostic industry and extensive background in molecular diagnostics including his former tenure as President and CEO of Roche Molecular Systems. We look forward to his invaluable insight as we continue to evolve as a company."

"In terms of second quarter results, our revenue of $32 million were in line with our expectations and continues to reflect the soft RFP volume we experienced in our Sales Services business. Gross margins of 15%, while down compared to last year, are in line with current industry norms. Our adjusted EBITDA loss of $1.5 million in the quarter was primarily driven by spending on our key strategic initiatives and lower gross profit," said Nancy Lurker, CEO.

Ms. Lurker continued, "As for our outlook for the remainder of the year, we continue to expect revenue in our core business to be down in the third quarter and for the full year compared to 2013. We still anticipate an operating loss in the range of $4 - $5 million and approximately breakeven adjusted EBITDA in the core business for the full year 2014. Given today's Asuragen transaction, we now see a modest amount of revenues from Interpace Diagnostic for 2014 and an operating loss in the range of $5 - $6 million from all Interpace Diagnostics activities including additional selling and marketing and pre-launch expenses to support the anticipated ramp up of revenue from the acquired Asuragen assets."

Second Quarter Business Review

Revenue- For the second quarter of 2014, revenue of $31.6 million was $5.7 million or 15% lower than the second quarter of 2013 driven by the natural expiration or reduction of contracts being executed in 2014 exceeding new contracts entered into in the company's Sales Services segment.

  • Sales Services revenue of $28.1 million was $4.2 million lower than the second quarter of 2013. New contract wins from the softer RFP volume experienced in the latter half of 2013 was not sufficient to offset the natural expiration or reduction of certain contracts.

  • Marketing Services revenue of $0.6 million was $1.0 million lower than the second quarter of 2013 due to fewer contract signings by Group DCA.

  • Product Commercialization Services revenue of $2.9 million was $0.4 million lower than the second quarter of 2013.

Gross Profit- For the second quarter of 2014, gross profit of $4.8 million was $2.1 million lower than the second quarter of 2013 and, as anticipated, the overall gross profit percentage decreased to 15% in 2014 from 18% in 2013.

  • Sales Services gross profit of $4.8 million was $0.5 million lower than the second quarter of 2013 due primarily to lower revenue and previously disclosed competitive pricing pressures.

  • Marketing Services gross profit for the second quarter of 2014 was a negative $0.5 million due to the decrease in revenue and increased costs associated with the launch of our new product, PD One.

  • Product Commercialization Services gross profit of $0.6 million was $0.4 million lower compared to the second quarter of 2013 primarily due to expenses related to one of our collaboration agreements for molecular diagnostic tests.

Total Operating Expenses- Total operating expenses for the second quarter of 2014 were $7.3 million as compared to $7.7 million for the same period in 2013. Included in second quarter 2014 expenses are $0.7 million of investment costs related to our molecular diagnostics strategic initiative. Excluding these costs, total operating expenses for the second quarter of 2014 were $6.6 million; $1.1 million lower than 2013 operating expenses.

Operating Income/Loss- The operating loss for the second quarter of 2014 was $2.5 million, compared to $0.8 million for the same period in 2013.  The 2014 operating loss was primarily the result of the anticipated lower revenue and margins as well as the company's investment in strategic initiatives.

Liquidity and Cash Flow- Adjusted EBITDA (a non-GAAP measure defined in the release) for the second quarter of 2014 was $(1.5) million compared to $0.2 million in the second quarter of 2013. Cash and cash equivalents at the end of the second quarter were $35.6 million, down $10.0 million from December 31, 2013 due primarily to increases in working capital requirements, timing of certain payments from customers and investments in our strategic initiatives. Factoring in the Asuragen acquisition and anticipated additional spending in Interpace Diagnostics, the company estimates year end 2014 cash of $22 - $25 million.

As of June 30, 2014, the company's cash equivalents were predominantly invested in U.S. Treasury money market funds and the company had no commercial debt.

Non-GAAP Financial Measures

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, PDI has provided a certain non-GAAP financial measure to help evaluate the results of its performance. The company believes that this non-GAAP financial measure, when presented in conjunction with comparable GAAP financial measure, is useful to both management and investors in analyzing the company's ongoing business and operating performance. The company believes that providing non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the company's financial results in the way that management views financial results.

In this document, the company discusses Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as operating income or loss, plus depreciation and amortization, non-cash stock-based compensation, and other non-cash expenses. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

Adjusted EBITDA (Unaudited)

($ in thousands)




2nd Quarter Ended


Six Months Ended




June 30,


June 30,




2014


2013


2014


2013











Operating (loss) income 

$       (2,523)


$           (847)


$       (4,020)


$         1,406

Depreciation and amortization

380


289


837


577

Stock compensation


668


722


1,358


1,073

Adjusted EBITDA


$       (1,475)


$            164


$       (1,825)


$         3,056

 

Conference Call

As previously announced, PDI will hold a conference call Thursday, August 14, 2014 to discuss financial and operational results of the second quarter ended June 30, 2014.  Details as follows:

Time: 8:30 AM (ET)
Dial-in numbers: (855) 592-8761 (U.S. and Canada) or (724) 924-4975
Conference ID#: 27904432

Live webcast: www.pdi-inc.com, under "Investor Relations"

The teleconference replay will be available three hours after completion through September 13, 2014 at (855) 859-2056 (U.S. and Canada) or (404) 537-3406. The replay pass code is 27904432. The archived web cast will be available for one year.

About PDI, Inc.

PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. PDI's Interpace Diagnostics division is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company's Contract Sales business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. Its Group DCA division is a pioneer in insight-driven digital communication services and integrated multichannel message delivery.

For more information about PDI, Inc. or Interpace Diagnostics, please visit http://www.pdi-inc.com and www.interpacediagnostics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, growth and profitability, actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance goals in PDI's incentive-based arrangements with customers or the inability to secure additional business. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's previously filed Annual Report on Form 10-K for the year ended December 31, 2013 and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

PDI, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(in thousands, except per share data)










Three Months Ended


Six Months Ended


June 30,


June 30,


2014


2013


2014


2013









Revenue, net

$         31,578


$         37,245


$      64,356


$        80,168

Cost of services

26,787


30,396


54,456


64,846

Gross profit

4,791


6,849


9,900


15,322









Compensation expense

3,862


4,914


7,403


9,069

Other selling, general and administrative expenses

3,452


2,782


6,517


4,847

Total operating expenses

7,314


7,696


13,920


13,916

Operating (loss) income 

(2,523)


(847)


(4,020)


1,406

Other expense, net

(13)


(24)


(30)


(34)

(Loss) income from continuing operations before








income tax

(2,536)


(871)


(4,050)


1,372

Provision for income tax

65


64


131


128

(Loss) income from continuing operations

(2,601)


(935)


(4,181)


1,244

(Loss) income  from discontinued operations, net of tax

(57)


52


(89)


(2)









Net (loss) income 

$          (2,658)


$             (883)


$       (4,270)


$          1,242









Basic (loss) income per share of common stock:








From continuing operations

$            (0.17)


$            (0.06)


$         (0.28)


$             0.08

From discontinued operations

(0.01)


-


(0.01)


-

Net (loss) income per basic share of common stock

$            (0.18)


$            (0.06)


$         (0.29)


$             0.08









Diluted (loss) income per share of common stock:








From continuing operations

$            (0.17)


$            (0.06)


$         (0.28)


$             0.08

From discontinued operations

(0.01)


-


(0.01)


-

Net (loss) income per diluted share of common stock

$            (0.18)


$            (0.06)


$         (0.29)


$             0.08









Weighted average number of common shares and








common share equivalents outstanding:








Basic

14,910


14,713


14,860


14,691

Diluted

14,910


14,713


14,860


15,154

 

Segment Data (Unaudited)

($ in thousands)










Sales


Marketing


PC



Services


Services


Services*


Consolidated

Three months ended June 30, 2014:








Revenue, net

$         28,067


$              614


$        2,897


$        31,578

Gross profit (loss)

$           4,765


$            (526)


$           552


$          4,791

Gross profit %

17.0%


-85.7%


19.1%


15.2%









Three months ended June 30, 2013:








Revenue, net

$         32,294


$           1,644


$        3,307


$        37,245

Gross profit

$           5,252


$              638


$           959


$          6,849

Gross profit %

16.3%


38.8%


29.0%


18.4%










Sales


Marketing


PC



Services


Services


Services*


Consolidated

Six months ended June 30, 2014:








Revenue, net

$         56,862


$          1,617


$        5,877


$        64,356

Gross profit (loss)

$           9,508


$            (694)


$        1,086


$          9,900

Gross profit %

16.7%


-42.9%


18.5%


15.4%









Six months ended June 30, 2013:








Revenue, net

$         70,519


$          3,185


$        6,464


$        80,168

Gross profit

$         12,571


$          1,022


$        1,729


$        15,322

Gross profit %

17.8%


32.1%


26.7%


19.1%









* Product Commercialization (PC) Services



 

 

Selected Balance Sheet Data (Unaudited)

($ in thousands)


 June 30, 


 December 31, 


2014


2013





Cash and cash equivalents

$         35,621


$         45,639





Total current assets

$         53,176


$         62,709

Total current liabilities

25,621


31,400

Working capital

$         27,555


$         31,309





Total assets

$         59,459


$         69,064

Total liabilities

$         30,107


$         36,585

Total stockholders' equity

$         29,352


$         32,479









Selected Cash Flow Data (Unaudited)

($ in thousands)


June 30,


2014


2013





Net (loss) income

$       (4,270)


$        1,242

Non-cash items:




     Depreciation and amortization

837


577

     Stock-based compensation

1,358


1,073

     Other

71


71

Net change in assets and liabilities

(6,284)


(3,537)

Net cash used in operations

$       (8,288)


$         (574)





Change in cash and cash equivalents

$     (10,018)


$      (1,760)

Logo - http://photos.prnewswire.com/prnh/20140114/NY45872LOGO

SOURCE PDI, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
SYS-CON Events announced today that Infranics will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Since 2000, Infranics has developed SysMaster Suite, which is required for the stable and efficient management of ICT infrastructure. The ICT management solution developed and provided by Infranics continues to add intelligence to the ICT infrastructure through the IMC (Infra Management Cycle) based on mathemat...
SYS-CON Events announced today that SD Times | BZ Media has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. BZ Media LLC is a high-tech media company that produces technical conferences and expositions, and publishes a magazine, newsletters and websites in the software development, SharePoint, mobile development and commercial UAV markets.
SYS-CON Events announced today that Cloudistics, an on-premises cloud computing company, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloudistics delivers a complete public cloud experience with composable on-premises infrastructures to medium and large enterprises. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a ...
Now that the world has connected “things,” we need to build these devices as truly intelligent in order to create instantaneous and precise results. This means you have to do as much of the processing at the point of entry as you can: at the edge. The killer use cases for IoT are becoming manifest through AI engines on edge devices. An autonomous car has this dual edge/cloud analytics model, producing precise, real-time results. In his session at @ThingsExpo, John Crupi, Vice President and Eng...
There are 66 million network cameras capturing terabytes of data. How did factories in Japan improve physical security at the facilities and improve employee productivity? Edge Computing reduces possible kilobytes of data collected per second to only a few kilobytes of data transmitted to the public cloud every day. Data is aggregated and analyzed close to sensors so only intelligent results need to be transmitted to the cloud. Non-essential data is recycled to optimize storage.
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., will discuss how these tools can be leveraged to develop a lasting competitive advanta...
SYS-CON Events announced today that HTBase will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. HTBase (Gartner 2016 Cool Vendor) delivers a Composable IT infrastructure solution architected for agility and increased efficiency. It turns compute, storage, and fabric into fluid pools of resources that are easily composed and re-composed to meet each application’s needs. With HTBase, companies can quickly prov...
"I think that everyone recognizes that for IoT to really realize its full potential and value that it is about creating ecosystems and marketplaces and that no single vendor is able to support what is required," explained Esmeralda Swartz, VP, Marketing Enterprise and Cloud at Ericsson, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
SYS-CON Events announced today that IoT Now has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. IoT Now explores the evolving opportunities and challenges facing CSPs, and it passes on some lessons learned from those who have taken the first steps in next-gen IoT services.
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, provided the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” used open source attack tools that are free and available for download by anybody. Attendees learned where to find and how to operate these tools for the purpose of testing their own IT infrastructure. The...
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.